PDCD1 and nasopharyngeal carcinoma: Hsu et al. [5] reported a phase Ib clinical trial about anti-PD-1 monoclonal antibody, pembrolizumab, in NPC with PD-L1 positive, and revealed its antitumor activity and manageable adverse events.